XENE Stock Summary and Trading Ideas (Xenon Pharmaceuticals - Common Shares | NASDAQ:XENE)

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Xenon Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol XENE.

As of October 15, 2026, XENE stock price climbed to $34.72 with 944,339 million shares trading.

XENE has a beta of 0.36, meaning it tends to be less sensitive to market movements. XENE has a correlation of 0.01 to the broad based SPY ETF.

XENE has a market cap of $3.36 billion. This is considered a Mid Cap stock.

Last quarter Xenon Pharmaceuticals - Common Shares reported $0 in Revenue and -$1.11 earnings per share. This fell short of revenue expectation by $-937,500 and exceeded earnings estimates by $.05.

In the last 3 years, XENE traded as high as $72.66 and as low as $26.74.

The top ETF exchange traded funds that XENE belongs to (by Net Assets): IWM, VTWO, IWO, IBB, TCAF.

XENE has underperformed the market in the last year with a price return of -14.4% while the SPY ETF gained +17.8%. XENE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.4% and -6.6%, respectively, while the SPY returned +3.0% and +1.3%, respectively.

XENE support price is $32.89 and resistance is $34.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XENE shares will trade within this expected range on the day.